Literature DB >> 6889815

Vitrectomy in uveitis associated with ankylosing spondylitis.

J B Belmont, J B Michelson.   

Abstract

Chronic recurrent iridocyclitis in three eyes of two patients with ankylosing spondylitis was associated with posterior spillover of inflammatory cells into the vitreous cavity. Continued inflammation resulted in significant vitreous opacification in all three eyes. After pars plana vitrectomy (two eyes) and cataract extraction with subtotal vitrectomy (one eye), visual acuity improved and stabilized in all three instances. Ocular inflammation was not appreciably exacerbated by surgical intervention. Vitreous opacification did not recur after vitrectomy, but visual improvement was limited because of chronic cystoid macular edema.

Entities:  

Mesh:

Year:  1982        PMID: 6889815     DOI: 10.1016/0002-9394(82)90354-3

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  5 in total

1.  Vitreous replacement by gas as a therapeutic modality in bacterial endophthalmitis.

Authors:  A M Mansour; E Ferguson; H Lucia; M Rajashekhar; H Li; T Margo
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1991       Impact factor: 3.117

2.  Pars plana vitrectomy in ocular Behçet's disease.

Authors:  M Soylu; N Demircan; A Pelit
Journal:  Int Ophthalmol       Date:  2001       Impact factor: 2.031

3.  Outcomes of early and late immunomodulatory treatment in patients with HLA-B27-associated chronic uveitis.

Authors:  Sofia Androudi; Periklis Brazitikos; Barbara Iaccheri; Tito Fiore; William Christen; Margherita Meniconi; C Stephen Foster
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2003-11-07       Impact factor: 3.117

4.  Long-term results of pars plana vitrectomy in the management of complicated uveitis.

Authors:  A Heiligenhaus; N Bornfeld; M H Foerster; A Wessing
Journal:  Br J Ophthalmol       Date:  1994-07       Impact factor: 4.638

Review 5.  [Therapeutic vitrectomy in uveitis: current status and recommendations].

Authors:  M D Becker; N Harsch; M Zierhut; J L Davis; F G Holz
Journal:  Ophthalmologe       Date:  2003-10       Impact factor: 1.059

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.